FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3209969737> ?p ?o ?g. }

• W3209969737 abstract "Objective: Report long-term follow-up study design and data from the phase 1 study of onasemnogene abeparvovec (AVXS-101) in SMA1. Background: Infants with SMA1 rapidly lose the ability to swallow and breathe, do not achieve normal developmental milestones, fail to thrive, suffer from frequent pulmonary infections, and lose the ability to communicate before succumbing to the disease. AVXS-101, a one-time GRT, treats the genetic root cause of SMA, deletion/loss of function of the survival motor neuron (SMN1) gene. It is designed for immediate, sustained expression of SMN protein, allowing rapid onset and durable effect. In the phase 1 trial (NCT02122952), 15 SMA1 patients received a one-time intravenous dose of AVXS-101, 3 at a lower dose (cohort 1) and 12 at the proposed therapeutic dose (cohort 2). There was unprecedented event-free survival and developmental motor milestones (Mendell N Engl J Med 2017). Design/Methods: Patients in the phase 1 study could rollover into a long-term follow-up study (NCT03421977). The primary objective is to collect long-term safety data by assessing incidence of serious adverse events, hospitalizations, and adverse events of special interest. Patients will have annual visits for 5 years followed by contact via phone annually for 10 years. Additionally, patient record transfers from their local physician and/or neurologist will be requested. Safety assessments will include medical history and record review, physical examination, clinical laboratory evaluation, and pulmonary assessments. Efficacy assessments will include physical examination to assess developmental milestones. Results: As of September 27, 2018, the oldest patients in cohort 1 and 2 are 59.2 and 52.1 months old, respectively, and free of permanent ventilation. Preliminary data, including survival and developmental milestones, will be presented. Conclusions: Patients treated with a one-time dose of AVXS-101 continue to gain strength, develop, and achieve new milestones, demonstrating a long-term, durable response. Disclosure: Dr. Mendell has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with AveXis, Inc. Dr. Lehman has nothing to disclose. Dr. McColly has nothing to disclose. Dr. Lowes has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with AveXis, Inc., Bristol Meyers-Squibb, Pfizer, and Sarepta Therapeutics. Dr. Lowes has received research support from Novartis and Sarepta Therapeutics. Dr. Alfano has nothing to disclose. Dr. Miller has nothing to disclose. Dr. Iammarino has nothing to disclose. Dr. Church has nothing to disclose. Dr. Ogrinc has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with AveXis, a Novartis company. Dr. L’Italien has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with AveXis, Inc.. Dr. Wells has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with AveXis, a Novartis company. Dr. Sproule has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities as an employee of AveXis, a Novartis company. Dr. Sproule has received compensation for serving on the Board of Directors of AveXis, a Novartis company. Dr. Feltner has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Acadia, Embera Neurtherapeutics, AveXis, Inc. Dr. Feltner has received compensation for serving on the Board of Directors of Embera Neurotherapeutics. Dr. Feltner holds stock and/or stock options in AveXis, Inc." @default.
• W3209969737 created "2021-11-08" @default.
• W3209969737 creator A5005685754 @default.
• W3209969737 creator A5015648461 @default.
• W3209969737 creator A5020474962 @default.
• W3209969737 creator A5025347858 @default.
• W3209969737 creator A5027076683 @default.
• W3209969737 creator A5035271470 @default.
• W3209969737 creator A5035946884 @default.
• W3209969737 creator A5039453462 @default.
• W3209969737 creator A5041763238 @default.
• W3209969737 creator A5047809221 @default.
• W3209969737 creator A5047869585 @default.
• W3209969737 creator A5052534937 @default.
• W3209969737 creator A5057207386 @default.
• W3209969737 date "2019-04-09" @default.
• W3209969737 modified "2023-10-05" @default.
• W3209969737 title "AVXS-101 Gene-Replacement Therapy (GRT) in Spinal Muscular Atrophy Type 1 (SMA1): Long-Term Follow-Up From the Phase 1 Clinical Trial (S25.006)" @default.
• W3209969737 hasPublicationYear "2019" @default.
• W3209969737 type Work @default.
• W3209969737 sameAs 3209969737 @default.
• W3209969737 citedByCount "0" @default.
• W3209969737 crossrefType "journal-article" @default.
• W3209969737 hasAuthorship W3209969737A5005685754 @default.
• W3209969737 hasAuthorship W3209969737A5015648461 @default.
• W3209969737 hasAuthorship W3209969737A5020474962 @default.
• W3209969737 hasAuthorship W3209969737A5025347858 @default.
• W3209969737 hasAuthorship W3209969737A5027076683 @default.
• W3209969737 hasAuthorship W3209969737A5035271470 @default.
• W3209969737 hasAuthorship W3209969737A5035946884 @default.
• W3209969737 hasAuthorship W3209969737A5039453462 @default.
• W3209969737 hasAuthorship W3209969737A5041763238 @default.
• W3209969737 hasAuthorship W3209969737A5047809221 @default.
• W3209969737 hasAuthorship W3209969737A5047869585 @default.
• W3209969737 hasAuthorship W3209969737A5052534937 @default.
• W3209969737 hasAuthorship W3209969737A5057207386 @default.
• W3209969737 hasConcept C126322002 @default.
• W3209969737 hasConcept C187212893 @default.
• W3209969737 hasConcept C197934379 @default.
• W3209969737 hasConcept C2778558090 @default.
• W3209969737 hasConcept C2779134260 @default.
• W3209969737 hasConcept C535046627 @default.
• W3209969737 hasConcept C71924100 @default.
• W3209969737 hasConcept C72563966 @default.
• W3209969737 hasConcept C73751289 @default.
• W3209969737 hasConceptScore W3209969737C126322002 @default.
• W3209969737 hasConceptScore W3209969737C187212893 @default.
• W3209969737 hasConceptScore W3209969737C197934379 @default.
• W3209969737 hasConceptScore W3209969737C2778558090 @default.
• W3209969737 hasConceptScore W3209969737C2779134260 @default.
• W3209969737 hasConceptScore W3209969737C535046627 @default.
• W3209969737 hasConceptScore W3209969737C71924100 @default.
• W3209969737 hasConceptScore W3209969737C72563966 @default.
• W3209969737 hasConceptScore W3209969737C73751289 @default.
• W3209969737 hasOpenAccess W3209969737 @default.
• W3209969737 hasRelatedWork W1538984046 @default.
• W3209969737 hasRelatedWork W1966887464 @default.
• W3209969737 hasRelatedWork W2187415529 @default.
• W3209969737 hasRelatedWork W2313603351 @default.
• W3209969737 hasRelatedWork W2318290358 @default.
• W3209969737 hasRelatedWork W2335033262 @default.
• W3209969737 hasRelatedWork W2546895264 @default.
• W3209969737 hasRelatedWork W2565990905 @default.
• W3209969737 hasRelatedWork W2804847357 @default.
• W3209969737 hasRelatedWork W2885835912 @default.
• W3209969737 hasRelatedWork W2889807054 @default.
• W3209969737 hasRelatedWork W2982997998 @default.
• W3209969737 hasRelatedWork W3036036947 @default.
• W3209969737 hasRelatedWork W3145549342 @default.
• W3209969737 hasRelatedWork W3194932058 @default.
• W3209969737 hasRelatedWork W3200628676 @default.
• W3209969737 hasRelatedWork W3202451489 @default.
• W3209969737 hasRelatedWork W3208753081 @default.
• W3209969737 hasRelatedWork W3209654249 @default.
• W3209969737 hasRelatedWork W380437619 @default.
• W3209969737 hasVolume "92" @default.
• W3209969737 isParatext "false" @default.
• W3209969737 isRetracted "false" @default.
• W3209969737 magId "3209969737" @default.
• W3209969737 workType "article" @default.